Survival, causes of death, and prognostic factors in systemic sclerosis: Analysis of 947 Brazilian patients

Journal of Rheumatology

Volumn 39, Issue 10, 2012, Pages 1971-1978

  Sampaio Barros, Percival D ^a   Bortoluzzo, Adriana B ^b   Marangoni, Roberta G ^a   Rocha, Luiza F ^a   Del Rio, Ana Paula T ^c   Samara, Adil M ^c   Yoshinari, Natalino H ^a   Marques Neto, João Francisco ^c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSPER INSTITUTE OF EDUCATION AND RESEARCH   (Brazil)

^c UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Causes of death; Heart involvement; Lung involvement; Prognosis; Survival analysis; Systemic sclerosis

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CENTROMERE ANTIBODY; CYCLOPHOSPHAMIDE; SCL 70 ANTIBODY;

ADULT; AGE DISTRIBUTION; ARTICLE; BRAZIL; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; DISEASE DURATION; FEMALE; FOLLOW UP; HEART DISEASE; HUMAN; INFECTION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MODIFIED RODNAN SKIN SCORE; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; ONSET AGE; OSTEOARTHROPATHY; PRIORITY JOURNAL; PROGNOSIS; RACE DIFFERENCE; SCORING SYSTEM; SEX DIFFERENCE; SURVIVAL TIME; SYSTEMIC SCLEROSIS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BRAZIL; CAUSE OF DEATH; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SCLERODERMA, SYSTEMIC; SEX FACTORS; SURVIVAL RATE;

EID: 84867227939     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.111582     Document Type: Article

References (49)

1. Karassa FB, Ioannidis JPA. Mortality in systemic sclerosis. Clin Exp Rheumatol 2008;26 Suppl 51:S85-93.
2. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940-4. (Pubitemid 46999798)
3. Steen VD, Medsger TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-44.
4. Tyndall AJ, Bannert B, Vonk M, Airó P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: A study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010;69:1809-15.
5. Kaburaki J, Lee CC, Kuwana M, Tojo T, Ikeda Y, Takano M, et al. Initial predictors of survival in patients with systemic sclerosis (scleroderma). Keio J Med 1992;41:141-5.
6. Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998;57:682-6. (Pubitemid 28558973)
7. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al. Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc). Systemic sclerosis: demographic, clinical, and serologic features and survival in 1012 Italian patients. Medicine 2002;81:139-53.
8. Mayes MD, Lacey JV, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003;48:2246-55. (Pubitemid 36959206)
9. Wynn J, Feneberg N, Matzer L, Cortada X, Armstrong W, Dillon JC, et al. Prediction of survival in progressive systemic sclerosis by multivariate analysis of clinical features. Am Heart J 1985;110:123-7. (Pubitemid 16119691)
10. Altman RD, Medsger TA Jr, Bloch DA, Michel BA. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991;34:403-13.
11. Lee P, Langevitz P, Alderdice CA, Aubrey M, Baer PA, Baron M, et al. Mortality in systemic sclerosis (scleroderma). Q J Med 1992;82:139-48.
12. Steen VD, Medsger TA Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001;44:2828-35. (Pubitemid 34016202)
13. Scussel-Lonzetti L, Joyal F, Raynauld JP, Roussin A, Rich E, Goulet JR, et al. Predicting mortality in systemic sclerosis: Analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine 2002;81:154-67. (Pubitemid 34218570)
14. Ruangjutipotan S, Kasitanon N, Louthrenoo W, Sukitawut W, Wichainun R. Causes of death and poor survival prognostic factors in Thai patients with systemic sclerosis. J Med Assoc Thai 2002;85:1204-9. (Pubitemid 36255032)
15. Simeon CP, Armadans L, Fonollosa V, Solans R, Selva A, Villar M, et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology 2003;42:71-5. (Pubitemid 36131570)
16. Czirják L, Kumánowics G, Varjú C, Nagy Z, Pakozdi A, Skekanecz Z, et al. Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 2008;67:59-63.
17. Jacobsen S, Ullman S, Shen GQ, Wiik A, Halberg P. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol 2001;28:2454-9. (Pubitemid 33031976)
18. Bulpitt KJ, Clements PL, Lachenbruch PA, Paulus HE, Peter JB, Agopian MS, et al. Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis). Ann Intern Med 1993;118:602-9. (Pubitemid 23102694)
19. Bryan C, Knight C, Black CM, Silman AJ. Prediction of five-year survival following presentation with scleroderma development of a simple model using three disease factors at first visit. Arthritis Rheum 1999;42:2660-5. (Pubitemid 30327188)
20. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, Medsger TA Jr, Lucas M, Michet CJ, et al. Mortality in systemic sclerosis: An international meta-analysis of individual patient data. Am J Med 2005;118:2-10. (Pubitemid 40082450)
21. Nishioka K, Katayama I, Kondo H, Shinkai H, Ueki H, Tamaki K, et al. Epidemiological analysis of prognosis of 496 Japanese patients with progressive systemic sclerosis (SSc). Scleroderma Research Committee Japan. J Dermatol 1996;23:677-82. (Pubitemid 26396727)
22. Arias-Nuñez MC, Llorca J, Vazquez-Rodrigues TR, Gomez-Acebo I, Miranda-Filloy JA, Martin J, et al. Systemic sclerosis in northwestern Spain: A 19-year epidemiologic study. Medicine 2008;87:272-80.
23. Martini G, Vittadello F, Kasapçopur O, Magni Manzoni S, Corona F, Duarte-Salazar C, et al. Factors affecting survival in juvenile systemic sclerosis. Rheumatology 2009;48:119-22.
24. Hachulla E, Carpentier P, Gressin V, Diot E, Allanore Y, Sibilia J, et al. Risk factors for death and the 3-year survival of patients with systemic sclerosis: The French ItinérAIR-Sclérodermie study. Rheumatology 2009;48:304-8.
25. Tuffanelli DL, Winkelmann RK. Systemic scleroderma. A clinical study of 727 cases. Arch Dermatol 1961;84:359-71.
26. Al-Dhaher FF, Pope J, Ouimet JM. Determinants of morbidity and mortality in systemic sclerosis in Canada. Semin Arthritis Rheum 2010;39:269-77.
27. Joven BE, Almodovar R, Carmona L, Carreira PE. Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: Results from a single university hospital. Semin Arthritis Rheum 2010;39:285-93.
28. Nihtyanova SI, Tang EC, Coghlan JG, Wells A, Black CM, Denton CP. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: A retrospective cohort study. Q J Med 2010;103:109-15.
29. Hashimoto A, Tejima S, Tono T, Suzuki M, Tanaka S, Matsui T, et al. Predictors of survival and causes of death in Japanese patients with systemic sclerosis. J Rheumatol 2011;38:1931-9.
30. Kuo CF, See LC, Yu KH, Chou IJ, Tseng WI, Chang HC, et al. Epidemiology and mortality of systemic sclerosis: A nationwide population study in Taiwan. Scand J Rheumatol 2011;40:373-8.
31. Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: A systematic review and meta-analysis of cohort studies. Rheumatology 2012;51:1017-26.
32. Masi AT, Rodnan GP, Medsger TA Jr, Altman RD, D'Angelo WA, Fries JF, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90. (Pubitemid 10101764)
33. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5. (Pubitemid 18073738)
34. Poormoghim H, Lucas M, Fertig N, Medsger TA Jr. Systemic sclerosis sine scleroderma: Demographic, clinical, and serologic factors and survival in forty-eight patients. Arthritis Rheum 2000;43:444-51. (Pubitemid 30395756)
35. Mathai SC, Hummers LK, Champion HC, Wigley FM, Zaiman A, Hassoun PM, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: Impact of interstitial lung disease. Arthritis Rheum 2009;60:569-77.
36. Chung L, Krishnan E, Chakravarty EF. Hospitalizations and mortality in systemic sclerosis: Results from the Nationwide Inpatient Sample. Rheumatology 2007;46:1808-13. (Pubitemid 350168296)
37. Vettori S, Cuomo G, Abignano G, Iudici M, Valentini G. Survival and death causes in 251 systemic sclerosis patients from a single Italian center. Reumatismo 2010;63:202-9.
38. Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998;41:1613-9. (Pubitemid 28459919)
39. Wipff J, Coriat R, Masciocchi M, Caramaschi P, Derk CT, Hachulla E, et al. Outcomes of Barrett's oesophagus related to systemic sclerosis: A 3-year EULAR Scleroderma Trials and Research prospective study. Rheumatology 2011;50:1440-4.
40. Alarcon GS. Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis. Infect Dis Clin North Am 2006;20:849-75. (Pubitemid 44762257)
41. Wooten M. Systemic sclerosis and malignancy: A review of the literature. South Med J 2008;101:59-62.
42. Olesen AB, Svaerke C, Farkas DK, Sorensen HT. Systemic sclerosis and the risk of cancer: A nationwide population-based cohort study. Br J Dermatol 2010;163:800-6.
43. Meyer O. Prognostic markers for systemic sclerosis. Joint Bone Spine 2006;73:490-4.
44. Assassi S, Del Junco D, Sutter K, McNearney TA, Reveille JD, Karnavas A, et al. Clinical and genetic factors predictive of mortality in early systemic sclerosis. Arthritis Rheum 2009;61:1403-11.
45. Wastowski IJ, Sampaio-Barros PD, Amstalden EMI, Palomino GM, Marques-Neto JF, Crispim JC, et al. HLA-G expression in the skin of patients with systemic sclerosis. J Rheumatol 2009;36:1230-4.
46. Kuwana M, Kaburaki J, Arnett FC, Howard RF, Medsger TA Jr, Wright TM. Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum 1999;42:465-74. (Pubitemid 29136094)
47. Reveille JD, Fischbach M, McNearney T, Friedman AW, Aguilar MB, Lisse J, et al. Systemic sclerosis in 3 US ethnic groups: A comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 2001;30:332-46. (Pubitemid 32298859)
48. Nietert PJ, Mitchell HC, Bolster MB, Shaftman SR, Tilley BC, Silver RM. Racial variation in clinical and immunological manifestations of systemic sclerosis. J Rheumatol 2006;33:263-8. (Pubitemid 43209301)
49. Nashid M, Khanna PP, Furst DE, Clements PJ, Maranian P, Seibold J, et al. Gender and ethnicity differences in patients with diffuse systemic sclerosis - Analysis from three large randomized clinical trials. Rheumatology 2011;50:335-42.